Home About us Contact
|
Home About us Contact | ||
|
|
||
Glucose Sensor (glucose + sensor)
Kinds of Glucose Sensor Selected AbstractsFlexible Ultrathin PolyDVB/EVB Composite Membranes for the Optimization of a Whole Blood Glucose SensorELECTROANALYSIS, Issue 4 2007Kerry Bridge Abstract An ultrathin composite membrane has been developed as the outer covering barrier in a model amperometric glucose oxidase enzyme electrode. The membrane was formed by cathodic electropolymerization of divinylbenzene/ethylvinylbenzene at the surface of a gold coated polyester support membrane. Permeability coefficients were determined for O2 and glucose across membranes with a range of polymer thicknesses. Anionic interferents (such as ascorbate), were screened from the working electrode via a charge exclusion mechanism. The enzyme electrode showed an initial 10% signal drift when first exposed to whole human blood over a period of 2 hours, after which responses remained essentially stable. Whole blood patient glucose determinations yielded a correlation coefficient of r2=0.99 compared to standard hospital analyses. [source] Polydivinylbenzene/Ethylvinylbenzene Composite Membranes for the Optimization of a Whole Blood Glucose SensorELECTROANALYSIS, Issue 1 2006Kerry Bridge Abstract A novel ultra thin polydivinylbenzene/ethylvinylbenzene composite membrane has been developed for use as the outer covering barrier in a model amperometric glucose oxidase enzyme electrode. The composite membrane was formed via the cathodic electropolymerization of divinylbenzene/ethylvinylbenzene at the surface of gold sputter coated host alumina membranes, (serving solely as a mechanical support for the thin polymer film). Permeability coefficients were determined for the enzyme substrates, O2 and glucose, across composite membranes formed with a range of polymer thicknesses. Due to the highly substrate diffusion limiting nature of the composite membrane, it was found that anionic interferents present in blood (such as ascorbate), were effectively screened from the working electrode via a charge exclusion mechanism, in a manner similar to previous findings within our laboratory. The enzyme electrode showed an initial 32% signal drift when first exposed to whole human blood over a period of 2 hours, after which time enzyme electrode responses remained essentially stable. Whole blood patient glucose determinations yielded a correlation coefficient of r2=0.97 in comparison to standard hospital analyses. [source] Glucose sensors: a review of current and emerging technologyDIABETIC MEDICINE, Issue 3 2009N. S. Oliver Abstract Glucose monitoring technology has been used in the management of diabetes for three decades. Traditional devices use enzymatic methods to measure glucose concentration and provide point sample information. More recently continuous glucose monitoring devices have become available providing more detailed data on glucose excursions. In future applications the continuous glucose sensor may become a critical component of the closed loop insulin delivery system and, as such, must be selective, rapid, predictable and acceptable for continuous patient use. Many potential sensing modalities are being pursued including optical and transdermal techniques. This review aims to summarize existing technology, the methods for assessing glucose sensing devices and provide an overview of emergent sensing modalities. [source] Glassy Carbon Paste Electrodes for the Determination of Fructosyl ValineELECTROANALYSIS, Issue 6 2010Hui-Ching Chien Abstract Nearly 200,million people worldwide have type-2 diabetes. Glucose sensors are routinely used for diagnosis; however, the relative amount of glycosylated hemoglobin (HbA1c) may be a better marker. A working electrode made from bare glassy carbon paste was used for sensing fructosyl valine (Fru-Val), a component of HbA1c. Amperometric measurements revealed a linear relationship between Fru-Val concentration and the sensing current. The square correlation coefficient and the sensitivity were 0.999 and 5.26,,A mM,1, respectively. The minimum detection limit was less than 0.05,mM. [source] Postprandial hyperglycaemia in type 2 diabetes: pathophysiological aspects, teleological notions and flags for clinical practiceDIABETES/METABOLISM: RESEARCH AND REVIEWS, Issue S2 2004Eleni I. Boutati Abstract Type 2 diabetes subjects carry an excess risk for micro- and macrovascular disease and a higher cardiovascular morbidity and mortality rate. The beneficial impact of tight glycaemic control,evidenced by the integrated marker of fasting glucose and postprandial glucose values, the HbA1c,for the prevention of microvascular complications is definitely confirmed. Over the past few years, several studies have identified postprandial hyperglycaemia as a better predictor of cardiovascular or even of all-cause mortality, as well as an independent risk factor for atherosclerosis. The continuous glucose monitoring could offer a rationale means for the detection of postprandial hyperglycaemia and ultimately for its effective management. Advances in technology keep a promise for a reliable, convenient and closer to the idea of the artificial endocrine pancreas glucose sensor. Subcutaneous glucose levels charted by one of the new sensors were found to be well correlated with venous glucose measurements. Intervention for a healthy lifestyle is frequently hampered by patients' poor compliance. The availability of diverse antidiabetic agents provides options for targeting the glycaemic goal and a choice more fitted to the particularized pathophysiology of each individual subject. Drugs targeting postprandial glycaemia may prove to represent the ,sine qua non' for the ,return' of postprandial glucose values at a ,non-deleterious' threshold, either as monotherapy for the early stages of the disease or as combination therapy later in the progression of diabetes. Copyright © 2004 John Wiley & Sons, Ltd. [source] Glucose sensors: a review of current and emerging technologyDIABETIC MEDICINE, Issue 3 2009N. S. Oliver Abstract Glucose monitoring technology has been used in the management of diabetes for three decades. Traditional devices use enzymatic methods to measure glucose concentration and provide point sample information. More recently continuous glucose monitoring devices have become available providing more detailed data on glucose excursions. In future applications the continuous glucose sensor may become a critical component of the closed loop insulin delivery system and, as such, must be selective, rapid, predictable and acceptable for continuous patient use. Many potential sensing modalities are being pursued including optical and transdermal techniques. This review aims to summarize existing technology, the methods for assessing glucose sensing devices and provide an overview of emergent sensing modalities. [source] Nocturnal hypoglycaemia in Type 1 diabetic patients, assessed with continuous glucose monitoring: frequency, duration and associationsDIABETIC MEDICINE, Issue 5 2007I. M. E. Wentholt Abstract Aims, We quantified the occurrence and duration of nocturnal hypoglycaemia in individuals with Type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) or multiple-injection therapy (MIT) using a continuous subcutaneous glucose sensor. Methods, A microdialysis sensor was worn at home by 24 patients on CSII (mean HbA1c 7.8 ± 0.9%) and 33 patients on MIT (HbA1c 8.7 ± 1.3%) for 48 h. Occurrence and duration of nocturnal hypoglycaemia were assessed and using multivariate regression analysis, the association between HbA1c, diabetes duration, treatment type (CSII vs. MIT), fasting and bedtime blood glucose values, total daily insulin dose and mean nocturnal glucose concentrations, and hypoglycaemia occurrence and duration was investigated. Results, Nocturnal hypoglycaemia , 3.9 mmol/l occurred in 33.3% of both the CSII- (8/24) and MIT-treated patients (11/33). Mean (± sd; median, interquartile range) duration of hypoglycaemia , 3.9 mmol/l was 78 (± 76; 57, 23,120) min per night for the CSII- and 98 (± 80; 81, 32,158) min per night for the MIT-treated group. Multivariate regression analysis showed that bedtime glucose value had the strongest association with the occurrence (P = 0.026) and duration (P = 0.032) of nocturnal hypoglycaemia. Conclusions, Microdialysis continuous glucose monitoring has enabled more precise quantification of nocturnal hypoglycaemia occurrence and duration in Type 1 diabetic patients. Occurrence and duration of nocturnal hypoglycaemia were mainly associated with bedtime glucose value. [source] Electrochemically Induced Formation of Surface-Attached Temperature-Responsive Hydrogels.ELECTROANALYSIS, Issue 9 2010Amperometric Glucose Sensors with Tunable Sensor Characteristics Abstract Employing thermally responsive hydrogels, the design of an amperometric glucose sensor is proposed. The properties of the biosensor can be modulated upon changing the temperature. Homo- and copolymers of N -isopropylacrylamide (NIPAm) and oligo(ethylene glycol) methacrylate (OEGMA) were prepared by electrochemically induced polymerization thus yielding surface-attached hydrogels. The growth of the films as well as the change in the film thickness in dependence from the temperature were investigated by means of an electrochemical quartz crystal microbalance (EQCM). The layer thickness in the dry state ranged from 20 to 120,nm. The lower critical solution temperature (LCST) of the hydrogel increases with increasing content of the more hydrophilic OEGMA. Hence, the swelling in aqueous electrolyte is composition dependent and can be adjusted by selecting a specific NIPAm to OEGMA ratio. All homo- and copolymer films showed good biocompatibility and no fouling could be observed during exposing the surfaces to human serum albumin. For amperometric glucose detection, glucose oxidase was entrapped in the films during electrochemically-induced polymerization. Both the apparent Michaelis constant (K and the apparent maximum current (i as determined by amperometry could be adjusted both by the film composition as well as the operation temperature. [source] Glucose Biosensor Mediated by 1,2-Diferrocenylethane in a Sono-Gel Composite ElectrodeELECTROANALYSIS, Issue 2-3 2007Barbara Ballarin Abstract An amperometric glucose biosensor was constructed based on a renewable carbon composite sono-gel matrix incorporating 1,2-diferrocenylethane as electron transfer mediator between the electrode and the active site of glucose oxidase. The enzyme was immobilized on the electrode surface by cross-linking with glutaraldehyde and bovine serum albumin. The process parameters for the fabrication of the biosensor and the influence of various experimental conditions (i.e., pH, temperature, operating potential) were investigated. Cyclic voltammetry and amperometric measurements were used to study the response of the glucose sensor, which displayed fast response time and good reproducibility. The analytical performances and the apparent Michaelis-Menten constant of the biosensor were evaluated. [source] Biosensors Based on Aligned Carbon Nanotubes Coated with Inherently Conducting PolymersELECTROANALYSIS, Issue 13 2003Mei Gao Abstract The use of multiwalled aligned carbon nanotubes provides a novel electrode platform for inherently conducting polymer based biosensors. The example used here to highlight the usefulness of such a platform is the polypyrrole based glucose oxidase system for detection of glucose. The use of these three dimensional electrodes offers advantages in that large accessible enzyme loadings can be obtained within an ultrathin layer. It has also been found that the detection of H2O2 at these new electrode structures containing iron loaded nanotube tips can be achieved at low anodic potentials. The result is a sensitive and selective glucose sensor. [source] Glucose sensing in the intestinal epitheliumFEBS JOURNAL, Issue 16 2003Jane Dyer Dietary sugars regulate expression of the intestinal Na+/glucose cotransporter, SGLT1, in many species. Using sheep intestine as a model, we showed that lumenal monosaccharides, both metabolisable and nonmetabolisable, regulate SGLT1 expression. This regulation occurs not only at the level of transcription, but also at the post-transcriptional level. Introduction of d -glucose and some d -glucose analogues into ruminant sheep intestine resulted in >,50-fold enhancement of SGLT1 expression. We aimed to determine if transport of sugar into the enterocytes is required for SGLT1 induction, and delineate the signal-transduction pathways involved. A membrane impermeable d -glucose analogue, di(glucos-6-yl)poly(ethylene glycol) 600, was synthesized and infused into the intestines of ruminant sheep. SGLT1 expression was determined using transport studies, Northern and Western blotting, and immunohistochemistry. An intestinal cell line, STC-1, was used to investigate the signalling pathways. Intestinal infusion with di(glucos-6-yl)poly(ethylene glycol) 600 led to induction of functional SGLT1, but the compound did not inhibit Na+/glucose transport into intestinal brush-border membrane vesicles. Studies using cells showed that increased medium glucose up-regulated SGLT1 abundance and SGLT1 promoter activity, and increased intracellular cAMP levels. Glucose-induced activation of the SGLT1 promoter was mimicked by the protein kinase A (PKA) agonist, 8Br-cAMP, and was inhibited by H-89, a PKA inhibitor. Pertussis toxin, a G-protein (Gi)-specific inhibitor, enhanced SGLT1 protein abundance to levels observed in response to glucose or 8Br-cAMP. We conclude that lumenal glucose is sensed by a glucose sensor, distinct from SGLT1, residing on the external face of the lumenal membrane. The glucose sensor initiates a signalling pathway, involving a G-protein-coupled receptor linked to a cAMP,PKA pathway resulting in enhancement of SGLT1 expression. [source] Glucose induction pathway regulates meiosis in Saccharomyces cerevisiae in part by controlling turnover of Ime2p meiotic kinaseFEMS YEAST RESEARCH, Issue 5 2008Misa Gray Abstract Several components of the glucose induction pathway, namely the Snf3p glucose sensor and the Rgt1p and Mth1p transcription factors, were shown to be involved in inhibition of sporulation by glucose. The glucose sensors had only a minor role in regulating transcript levels of the two key regulators of meiotic initiation, the Ime1p transcription factor and the Ime2p kinase, but a major role in regulating Ime2p stability. Interestingly, Rgt1p was involved in glucose inhibition of spore formation but not inhibition of Ime2p stability. Thus, the glucose induction pathway may regulate meiosis through both RGT1- dependent and RGT1- independent pathways. [source] Polythiophene-Fullerene Based Photodetectors: Tuning of Spectral Response and Application in Photoluminescence Based (Bio)Chemical SensorsADVANCED MATERIALS, Issue 37 2010Kanwar S. Nalwa A photoluminescence (PL)-based oxygen and glucose sensor utilizing inorganic or organic light emitting diode as the light source, and polythiophene:fullerene type bulk-heterojunction devices as photodetectors, for both intensity and decay-time based monitoring of the sensing element's PL. The sensing element is based on the oxygen-sensitive dye Pt-octaethylporphyrin embedded in a polystyrene matrix. [source] Insulin pumps: from inception to the present and toward the futureJOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Issue 2 2010F. M. Alsaleh BPharm MSc Summary As an alternative to the usual insulin injections, insulin pumps have been introduced as an advanced method of insulin delivery for managing type 1 diabetes mellitus patients. This review documents the history of insulin pump development and the production of ,smart pumps' that offer patients greater dosing accuracy, flexibility, and ease of use. This has resulted in an increase in the number of insulin pump users around the world. This paper also provides a comprehensive survey of the pumps currently available on the market and their specifications. Unique features of each product and the drawbacks are addressed in the review. The future direction of insulin pump development is targeted toward closing the loop, to allow feedback control between an insulin pump and a glucose sensor, and hence finer adjustment of insulin delivery rates as required. [source] Low-fat vs. high-fat bedtime snacks in children and adolescents with type 1 diabetesPEDIATRIC DIABETES, Issue 4pt1 2008Darrell Wilson Objective:, The purpose of this study was to determine whether, in a group of children with type 1 diabetes using insulin pump, a prebedtime snack with a relatively high fat content provides greater protection from nocturnal hypoglycemia than a snack containing the same amount of carbohydrate and protein but a lower fat content. Research design and methods:, Ten subjects, aged 6 to <18 yr, in a trial evaluating the Abbott Navigator glucose sensor, agreed to this ancillary study. On 12 or more separate nights, each subject was randomized by a Web site to a carbohydrate,low-fat (30 g CHO, 2.5 g protein, and 1.3 g fat; 138 kcal) snack or a carbohydrate,high-fat (30 g CHO, 2 g protein, and 20 g fat; 320 kcal) snack. Subjects used their usual evening snack algorithm to determine the size (in 15-g carbohydrate increments) and insulin dosage. Results:, Average glucose on 128 valid study nights before snack was similar in both groups. The proportion of nights with hypoglycemia (a sensor or meter glucose value ,70 mg/dL) was similar in both groups (19% high fat vs. 20% low fat), as was the proportion of nights with hyperglycemia (a glucose ,200 mg/dL and at least 50 mg/dL above baseline, 35% high fat vs. 30% low fat). Conclusions:, There were no statistical differences between the high- and low-fat snacks on the frequency of hyperglycemia or hypoglycemia. This study highlights the feasibility of web-based research in patients' home environment. [source] Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator)PEDIATRIC DIABETES, Issue 2 2008Diabetes Research In Children Network (DirecNet) Study Group Background:, There are no published guidelines for use of real-time continuous glucose monitoring data by a patient; we therefore developed the DirecNet Applied Treatment Algorithm (DATA). The DATA provides algorithms for making diabetes management decisions using glucose values: (i) in real time which include the direction and rate of change of glucose levels, and (ii) retrospectively based on downloaded sensor data. Objective:, To evaluate the use and effectiveness of the DATA in children with diabetes using a real-time continuous glucose sensor (the FreeStyle Navigator). Subjects:, Thirty children and adolescents (mean ± standard deviation age = 11.2 ± 4.1 yr) receiving insulin pump therapy. Methods:, Subjects were instructed on use of the DATA and were asked to download their Navigator weekly to review glucose patterns. An Algorithm Satisfaction Questionnaire was completed at 3, 7, and 13 wk. Results:, At 13 wk, all of the subjects and all but one parent thought that the DATA gave good, clear directions for insulin dosing, and thought the guidelines improved their postprandial glucose levels. In responding to alarms, 86% of patients used the DATA at least 50% of the time at 3 wk, and 59% reported doing so at 13 wk. Similar results were seen in using the DATA to adjust premeal bolus doses of insulin. Conclusions:, These results show the feasibility of implementing the DATA when real-time continuous glucose monitoring is initiated and support its use in future clinical trials of real-time continuous glucose monitoring. [source] Glucose oxidase electrodes of polyaniline, poly(o -toluidine) and their copolymer as a biosensor: a comparative studyPOLYMERS FOR ADVANCED TECHNOLOGIES, Issue 6 2004D. D. Borole Abstract A simple technique is described for constructing a glucose sensor by the entrapment of glucose oxidase (GOD) in a polyaniline (PA), poly(o -toluidine) (POT) and their copolymer poly(aniline-co- o -toluidine) (PA-co-POT) thin films, which were electrochemically deposited on a platinum plate in phosphate and acetate buffer. The maximum current response was observed for PA, POT, and PA-co-POT GOD electrodes at pH 5.5 and potential 0.60,V (v. Ag/AgCl). The phosphate buffer gives fast response as compared to acetate buffer in amperometric measurements. PA GOD electrode shows the fastest response followed by PA-co-POT and POT GOD electrodes. Copyright © 2004 John Wiley & Sons, Ltd. [source] The future of glucose sensors,using the technology within a clinical serviceDIABETIC MEDICINE, Issue 3 2009D. E. Flanagan No abstract is available for this article. [source] Continuous glucose monitoring and closed-loop systemsDIABETIC MEDICINE, Issue 1 2006R. Hovorka Abstract Background The last two decades have witnessed unprecedented technological progress in the development of continuous glucose sensors, resulting in the first generation of commercial glucose monitors. This has fuelled the development of prototypes of a closed-loop system based on the combination of a continuous monitor, a control algorithm, and an insulin pump. Method A review of electromechanical closed-loop approaches is presented. This is followed by a review of existing prototypes and associated glucose sensors. A literature review was undertaken from 1960 to 2004. Results Two main approaches exist. The extracorporeal s.c.,s.c. approach employs subcutaneous glucose monitoring and subcutaneous insulin delivery. The implantable i.v.,i.p. approach adopts intravenous sampling and intraperitoneal insulin delivery. Feasibility of both solutions has been demonstrated in small-scale laboratory studies using either the classical proportional,integral,derivative controller or a model predictive controller. Performance in the home setting has yet to be demonstrated. Conclusions The glucose monitor remains the main limiting factor in the development of a commercially viable closed-loop system, as presently available monitors fail to demonstrate satisfactory characteristics in terms of reliability and/or accuracy. Regulatory issues are the second limiting factor. Closed-loop systems are likely to be used first by health-care professionals in controlled environments such as intensive care units. [source] Development of Prototype Wireless Transmission Measurement for Glucose in Subcutaneous and Brain StriatumELECTROANALYSIS, Issue 9 2008Farook Ahmad Abstract Monitoring of glucose in subcutaneous and brain striatum have been extensively studied in the past. While biocompatibility was one of the limitations, others included the messy measuring equipments preclude monitoring in a complex environment. This study tried to establish an amperometric measurement of glucose in pre- and post-insulin-administration on diabetic and hyperglycemia rats via wireless. The results have indicated that the wireless sensing kit used was capable of monitoring glucose in both subcutaneous and brain. The physiological data have also shown a new insight on the fabrication of implantable glucose sensors. [source] Combined phylogenetic and neighbourhood analysis of the hexose transporters and glucose sensors in yeastsFEMS YEAST RESEARCH, Issue 4 2009Margarida Palma Abstract The sugar porter family in yeasts encompasses a wide variety of transporters including the hexose transporters and glucose sensors. We analysed a total of 75 members from both groups in nine hemiascomycetous species, with complete and well-annotated genomes: Saccharomyces cerevisiae, Candida glabrata, Zygosaccharomyces rouxii, Kluyveromyces thermotolerans, Saccharomyces kluyverii, Kluyveromyces lactis, Eremothecium gossypii, Debaryomyces hansenii and Yarrowia lipolytica. We present a model for the evolution of the hexose transporters and glucose sensors, supported by two types of complementary evidences: phylogeny and neighbourhood analysis. Five lineages of evolution were identified and discussed according to different mechanisms of gene evolution: lineage A for HXT1, HXT3, HXT4, HXT5, HXT6 and HXT7; lineage B for HXT2 and HXT10; lineage C for HXT8; lineage D for HXT14; and lineage E for SNF3 and RGT2. [source] Thin semitransparent gels containing phenylboronic acid: porosity, optical response and permeability for sugarsJOURNAL OF MOLECULAR RECOGNITION, Issue 2 2008Alexander E. Ivanov Abstract Radical copolymerization of acrylamide (Am) (90,mol%) with N -acryloyl- m -aminophenylboronic acid (NAAPBA) (10,mol%) carried out on the surface of glass slides in aqueous solution and in the absence of chemical cross-linkers, resulted in the formation of thin semitransparent gels. The phenylboronic acid (PBA) ligand density was ca. 160,µmol/ml gel. The gels exhibited a macroporous structure and displayed optical response to sucrose, lactose, glucose and fructose in 50,mM sodium phosphate buffer, in the pH range from 6.5 to 7.5. The response was fairly reversible and linearly depended on glucose concentration in the wide concentration range from 1 to 60,mM at pH 7.3. The character of response was explained by the balance of two competing equilibrium processes: binding of glucose to phenylboronate anions and binary hydrophobic interactions of neutral PBA groups. The apparent diffusion coefficient of glucose in the gels was ca. 2.5,×,10,7,cm2/s. A freshly prepared gel can be used daily for at least 1 month without changes in sensitivity. Autoclaving (121°C, 1.2 bar, 10,min) allows for the gels sterilization, which is important for their use as glucose sensors in fermentation processes. Copyright © 2008 John Wiley & Sons, Ltd. [source] Glucose-sensitive holographic sensors,JOURNAL OF MOLECULAR RECOGNITION, Issue 3 2004S. Kabilan Abstract Holographic sensors for monitoring glucose were fabricated from hydrogel films containing chemical ligands based on phenylboronic acid. The films were transformed into reflection holograms using a diffusion method coupled with exposure to laser light. The diffraction wavelength of the holograms was used to monitor the swelling of the hydrogel film in the presence of glucose. Fully reversible changes in diffraction wavelength were demonstrated, highlighting the potential for using these holograms as glucose sensors. Copyright © 2004 John Wiley & Sons, Ltd. [source] Past, present, and future of insulin pump therapy: better shot at diabetes controlMOUNT SINAI JOURNAL OF MEDICINE: A JOURNAL OF PERSONALIZED AND TRANSLATIONAL MEDICINE, Issue 4 2008Jennifer Sherr MD Abstract With the advent of continuous subcutaneous insulin infusion therapy and the findings of the Diabetes Control and Complications Trial, the management of type 1 diabetes has changed drastically. Over the past 30 years since its development, the effectiveness of continuous subcutaneous insulin infusion has been assessed in comparison with other modes of intensive treatment. Additionally, improvements in pump delivery systems have been made. Here, the findings of the studies on pump therapy are reviewed. Selection criteria of patients for pump use and how to initiate pump therapy are presented. Finally, newer findings on continuous glucose sensors are discussed as the next era of pump therapy continues to focus on the goal of developing an artificial pancreas. Mt Sinai J Med 75:352,361, 2008. © 2008 Mount Sinai School of Medicine [source] Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapyPEDIATRIC DIABETES, Issue 2 2009Diabetes Research in Children Network (DirecNet) Study Group Objective:, For continuous glucose sensors to improve the treatment of children with type 1 diabetes (T1D), they must be accurate, comfortable to wear, and easy to use. We conducted a pilot study of the FreeStyle NavigatorÔ Continuous Glucose Monitoring System (Abbott Diabetes Care) to examine the feasibility of daily use of a continuous glucose monitor (CGM) in an extended ambulatory setting. Methods:, Following a 13-wk trial of daily Navigator use, 45 children with T1D [10.7 ± 3.7 yr, range 4.6,17.6, 24 using insulin pumps; continuous subcutaneous insulin infusion (CSII) and 21 using glargine-based multiple daily injections (MDI)] used the Navigator for an additional 13 wk. Results:, Navigator use was initially slightly higher in the CSII users than in the MDI users but declined similarly in both groups by 22,26 wk. After 26 wk, 11 (46%) of 24 CSII users and 7 (33%) of 21 MDI users were using the CGM at least 5 d a week. No baseline demographic or clinical factors were predictive of the amount of sensor use at 26 wk. However, Navigator use during weeks 1,13 and scores on a CGM satisfaction survey at 13 wk were predictive of use in weeks 22,26. Conclusions:, CGM was generally well-tolerated in children with T1D for more than 6 months, and early acceptance of CGM was predictive of extended use of the device. Although many subjects and parents found CGM valuable, the declining usage over time underscores the need to develop new technologies and strategies to increase acceptance, effectiveness, and long-term use of these devices in youth with T1D. [source] | ||||||||||||||||